Tempus AI is trading at $67.08, up 4.26% during the October 20 session; no reliable report identified a specific catalyst.
- On October 19, Tempus AI announced positive ESMO study results: its AI-enabled screening panel showed greater than 80% sensitivity across 12 biomarkers in advanced lung cancer cases. Available reporting does not establish this recent news caused the gain.
- Broader market signals are mixed, and supplied index data show no clear same-direction explanation.
- Intraday volume information was unavailable.